Illumina (NASDAQ:ILMN) Hits New 52-Week High on Analyst Upgrade

Illumina, Inc. (NASDAQ:ILMN)’s stock price reached a new 52-week high during mid-day trading on Monday after Royal Bank Of Canada raised their price target on the stock from $230.00 to $310.00. Royal Bank Of Canada currently has an outperform rating on the stock. Illumina traded as high as $281.46 and last traded at $282.5770, with a volume of 803535 shares. The stock had previously closed at $273.04.

Several other equities analysts have also weighed in on ILMN. TD Cowen raised their price objective on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Argus boosted their target price on shares of Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday. Barclays raised their target price on shares of Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a report on Friday, July 31st. Finally, Leerink Partners lifted their price target on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $219.69.

Insiders Place Their Bets

In related news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 2,061,850 shares of company stock valued at $436,479,102. Company insiders own 2.90% of the company’s stock.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Royal Bank of Canada raised its price target for Illumina from $230 to $310 and maintained an “outperform” rating. The revised target implies additional upside from the stock’s current level and helped support buying momentum. Royal Bank Of Canada Issues Positive Forecast for Illumina Stock Price
• Positive Sentiment: RBC also characterized Illumina’s clinical sequencing revenue as a durable mid-teens growth business, reinforcing expectations for sustained demand for sequencing instruments, consumables and related services. Illumina’s Clinical Sequencing Revenue Seen as Durable Mid-Teens Grower
• Positive Sentiment: Illumina reached a new one-year high following the analyst upgrade, indicating strong market momentum. The move follows recent increases to analyst targets, the company’s higher 2026 guidance, and its addition to the S&P 500, which can increase demand from index-tracking funds. Illumina Sets New One-Year High on Analyst Upgrade
• Neutral Sentiment: The rally appears driven primarily by follow-through from earlier catalysts rather than a new earnings release. Illumina’s latest reported quarter exceeded consensus estimates for revenue and adjusted earnings, while full-year 2026 guidance was raised.
• Negative Sentiment: Quiver Quantitative data shows substantial insider selling over the past six months, with no reported open-market purchases. This may signal profit-taking or create a valuation overhang, particularly after the stock’s sharp advance.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Illumina in the 2nd quarter valued at approximately $3,374,423,000. Primecap Management Co. CA purchased a new position in Illumina during the 2nd quarter worth approximately $617,981,000. Jupiter Topco LLC acquired a new stake in Illumina during the 2nd quarter valued at $358,652,000. WCM Investment Management LLC raised its stake in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Illumina in the second quarter valued at $293,846,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Price Performance

The company has a market cap of $44.35 billion, a PE ratio of 54.79, a price-to-earnings-growth ratio of 3.87 and a beta of 1.41. The stock has a fifty day moving average price of $221.46 and a 200-day moving average price of $177.17. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.Illumina’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

About Illumina

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.